ReviewInternational journal of clinical and experimental pathology2017
HER-2 status and its clinicopathologic significance in breast cancer in patients from southwest China: re-evaluation of correlation between results from FISH and IHC.
Review in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dynamic Evolution of HER2 Expression Following Neoadjuvant Therapy and Its Association With Treatment Response and Prognosis in Breast Cancer: A Large-Scale Retrospective Study.World journal of surgery · 2026Article
- Article
- A deep learning approach with subregion partition in MRI image analysis for metastatic brain tumor.Frontiers in neuroinformatics · 2022Article
- Radiomics Nomogram Based on Radiomics Score from Multiregional Diffusion-Weighted MRI and Clinical Factors for Evaluating HER-2 2+ Status of Breast Cancer.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to re-evaluate the concordance between FISH and IHC for HER-2 status, and evaluate its clinicopathologic significance in breast cancer by the new guideline (2014) in China. We determined the HER-2 status in 589 cases of invasive breast cancer, the concordance and correlation between these two results and their relationship to cliniopathological characteristics were evaluated. The rate of HER-2 gene amplification identified by FISH was 31.07% (183/589). Concordance was detected in 93.67% with IHC 0/+, 32.26% in IHC 2+, and 61.16% in IHC 3+. The concordance of 54.67% was observed with a Kappa coefficient of 0.189 (
Indexed as
Identifiers
31966566PMC6965270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.